| Quantifying the effect of metformin treatment and dose on glycemic control. | |
| | |
MedLine Citation:
|
PMID: 22275444 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE Metformin is the first-line oral medication recommended for glycemic control in patients with type 2 diabetes. We reviewed the literature to quantify the effect of metformin treatment on glycated hemoglobin (HbA(1c)) levels in all types of diabetes and examine the impact of differing doses on glycemic control. RESEARCH DESIGN AND METHODS MEDLINE, EMBASE, and the Cochrane Library were searched from 1950 to June 2010 for trials of at least 12 weeks' duration in which diabetic patients were treated with either metformin monotherapy or as an add-on therapy. Data on change in HbA(1c) were pooled in a meta-analysis. Data from dose-comparison trials were separately pooled. RESULTS A total of 35 trials were identified for the main analysis and 7 for the dose-comparison analysis. Metformin monotherapy lowered HbA(1c) by 1.12% (95% CI 0.92-1.32; I(2) = 80%) versus placebo, metformin added to oral therapy lowered HbA(1c) by 0.95% (0.77-1.13; I(2) = 77%) versus placebo added to oral therapy, and metformin added to insulin therapy lowered HbA(1c) by 0.60% (0.30-0.91; I(2) = 79.8%) versus insulin only. There was a significantly greater reduction in HbA(1c) using higher doses of metformin compared with lower doses of metformin with no significant increase in side effects. CONCLUSIONS Evidence supports the effectiveness of metformin therapy in a clinically important lowering of HbA(1c) used as monotherapy and in combination with other therapeutic agents. There is potential for using higher doses of metformin to maximize glycemic control in diabetic patients without increasing gastrointestinal effects. |
| | |
Authors:
|
Jennifer A Hirst; Andrew J Farmer; Raghib Ali; Nia W Roberts; Richard J Stevens |
Related Documents
:
|
2463884 - Pharmacokinetics and distribution of heparin-binding growth factor i (endothelial cell ... 9100604 - Diurnal variations in twenty-four-hour energy expenditure during growth hormone treatme... 14551324 - Multiple hormones act sequentially to mediate a susceptible tomato pathogen defense res... 7228864 - Type i collagen fibrillogenesis in vitro. additional evidence for the assembly mechanism. 8137684 - Linear loss of insulin secretory capacity during the last six months preceding iddm. no... 7366794 - Measurement of mouse brain glucose utilization in vivo using [u-14c]glucose. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Diabetes care Volume: 35 ISSN: 1935-5548 ISO Abbreviation: Diabetes Care Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7805975 Medline TA: Diabetes Care Country: United States |
Other Details:
|
Languages: eng Pagination: 446-54 Citation Subset: IM |
Affiliation:
|
Corresponding author: Jennifer A. Hirst, jennifer.hirst@phc.ox.ac.uk. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control ...
Next Document: 'My feet - visible, but ignored . . . ' A qualitative study of foot care for people with rheumatoid ...